AVBCC Value-Based Voices

Who Gets Access? Understanding the New Reality of Cancer Drug Coverage

Are oncology treatments losing their "special status" with payers? In this episode of Value-Based Voices, host Brian Reid, MS, Principal of Reid Strategic and author of

AI at the Point of Care: Inside OpenEvidence's Approach to Smarter Clinical Decisions

Artificial intelligence is rapidly reshaping healthcare, but what does that look like in the day-to-day practice of oncology? In this episode of AVBCC's Value-Based

From Patient to Person: Redefining Cancer Care at the AVBCC LA Regional Collaborative

In this episode of Value‑Based Voices, host Deirdre “Dee” Saulet, PhD, Chief Strategy Officer, Jasper Health, and AVBCC Southwest Regional Collaborative Co-Chair, sits do

Red Tape: Real Consequences for Patients with Cancer

What happens when patients with cancer spend weeks navigating insurance requirements before receiving physician-prescribed care? In our latest episode of Value-Based Voi

Part D Upheaval: Why the Cancer Community Needs to Pay Attention

In this episode of Value-Based Voices, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies, and AVBCC Board Member, sits down with Joel White, Partner and H

Can the U.S. Keep Its Edge? FDA Policy, China’s Momentum, and the Future of Innovation

In this follow up conversation, Jayson Slotnik, JD, MPH, Partner at Health Policy Strategies and AVBCC Board Members, and Steve Usdin, Senior Editor, Washington, BioCentu

The Future of the FDA: What Comes Next?

In this first of a 2-part series featuring Steve Usdin, Senior Editor, Washington, BioCentury Publications, host Jayson Slotnik, JD, MPH, Partner at Health Policy Strateg

Reflections on the NCCN

In this episode of Value-Based Voices, we delve into the mission and inner workings of the NCCN, a cornerstone organization shaping cancer treatment standards in the U.S.

Advancing Cancer Research and Innovation through Collaboration at GCRIS 2026

We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices. Join GCRIS Scientif

Breaking the Model: Can Value-Based Insurance Deliver?

Most cancer drugs today are more effective and accessible than ever—yet patients often face crushing costs because our healthcare system still values profit over patient

From the Human Genome Project to 48 Hours: The Rapid Evolution of Tumor Biology

Most treatments and diagnostics once took years and hundreds of millions of dollars. Today, it costs less than $100,000 to sequence a genome and open the door to tailored

Navigating Value and Policy in U.S. Cancer Care and Pharma Pricing

International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, j

Most Favored Nation and What's Next

Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America?  In this episo

AI Revolution: Breaking Pharmacy Chains with Harry Travis, BS Pharm, MBA, and Ira Klein, MD, MBA, FACP

There are countless opportunities hidden in the data-driven tasks pharmacists do every day, and AI is ready to unlock them. But what happens when automation dramatically

Consolidation Versus Independence in Cancer Care

Is consolidation in cancer care truly the best path forward, or does independence offer greater benefits? In this episode of Value-Based Voices Sarah Alwardt, PhD, Presi

Insights from JP Morgan 2026 with Liz Fowler, PhD, JD

Commercial health plans may have been missing from J.P. Morgan 2026, but government had a big presence! Value-Based Voices host Burt Zweigenhaft, PhD, and nationally reco

More Insights from JP Morgan 2026 with Jeff Berkowitz, JD

Where was the drama at JP Morgan this year? Host Burt Zweigenhaft, PhD, and seasoned healthcare executive Jeff Berkowitz, JD, debate why the 2026 meeting seemed to be mis